Right, but GP was misrepresenting this. Having phases 1 and 2 overlap when phase 1 is clearly going well was at worst a risk to the phase 2 participants. It wasn't skimping on the length of phase 2 or 3, so there was never an increased risk of dangerous vaccines for the public.
> Notice this probably played a role in the fact that the clinical trials didn't reveal that the vaccines didn't have much effect in preventing transmission (although severity of symptoms was clearly reduced).
I don't think measuring reduction in transmission is a primary concern of vaccine trials? It also seems quite hard to do, without a significant proportion of the population being vaccinated.